Drugs /

selective estrogen receptor degrader srn-927

Back to Drugs List

Overview

NCI Definition [1]:
Definition: An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, SERD SRN-927 specifically binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.

Clinical Trials

View Clinical Trials for selective estrogen receptor degrader srn-927

Selective estrogen receptor degrader srn-927 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating selective estrogen receptor degrader srn-927, 1 is phase 1 (0 open).

ER Positive, HER2 Deficient Expression, and HER2 Negative are the most frequent biomarker inclusion criteria for selective estrogen receptor degrader srn-927 clinical trials.

Breast carcinoma is the most common disease being investigated in selective estrogen receptor degrader srn-927 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Selective Estrogen Receptor Degrader Srn-927
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating selective estrogen receptor degrader srn-927 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
serd srn-927, srn-927, selective estrogen receptor degrader srn-927
NCIT ID [1]:
C120037

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.